The AACR Annual Meeting took place in San Diego, CA from April 12-16, 2008. A study highlighted the development of a new anti-
CD19 antibody, which is a receptor found on B cells and is a potential target for treating
lymphoid cancers. The current standard treatment for
Non-Hodgkin Lymphoma (NHL) and certain
leukemias, which involves chemotherapy and
rituximab, often leads to relapse, indicating a need for alternative therapies.
The research introduced an innovative humanized anti-CD19 antibody, engineered to have enhanced cytotoxicity against
cancer cell lines and primary cancer cells. Key attributes of this antibody include a higher affinity for
Fc gamma receptors, improved effector functions, and notably increased potency against tumors. The antibody was designed to have reduced immunogenicity, increased binding strength, and greater stability.
An unexpected finding was the low rate of internalization observed for this antibody, prompting further investigation into various mechanisms of cytotoxicity. The engineered antibody showed significantly enhanced potency in antibody-dependent cell-mediated cytotoxicity (ADCC) assays when compared to both rituximab and a non-engineered version of the antibody. It was particularly effective against
chronic lymphocytic leukemia (CLL),
B-acute lymphoblastic leukemia (B-ALL), and
hairy cell leukemia (HCL).
The study also demonstrated that the engineered antibody induced potent ADCC in primary patient-derived
ALL and
MCL cells, outperforming both rituximab and the non-engineered anti-CD19 IgG1. Additionally, it showed increased phagocytosis and stronger anti-proliferative apoptotic activity compared to rituximab.
In vivo studies using xenograft mouse models indicated that the engineered antibody provided significant protection against tumor growth and metastasis. The findings suggest that this Fc-engineered anti-CD19 antibody, with its enhanced effector functions, is a promising candidate for the next generation of immunotherapies for various types of leukemia and
lymphomas.
How to Use Synapse Database to Search and Analyze Translational Medicine Data?
The transational medicine section of the Synapse database supports searches based on fields such as drug, target, and indication, covering the T0-T3 stages of translation. Additionally, it offers a historical conference search function as well as filtering options, view modes, translation services, and highlights summaries, providing you with a unique search experience.

Taking obesity as an example, select "obesity" under the indication category and click search to enter the Translational Medicine results list page. By clicking on the title, you can directly navigate to the original page.

By clicking the analysis button, you can observe that GLP-1R treatment for obesity has gained significant attention over the past three years, with preclinical research still ongoing in 2023. Additionally, there are emerging potential targets, such as GDF15, among others.

Click on the image below to go directly to the Translational Medicine search interface.
